Governance at a Glance
|Board Members||Audit||Compensation||Nominating and Corporate Governance|
Harold E. “Barry” Selick, Ph.D.
Harold E. “Barry” Selick, Ph.D. has served as a member of Molecular Templates’ Board of Directors since August 2017. He is currently the Vice-Chancellor of Business Development, Innovation, and Partnerships at the University of California, San Francisco, a position that he has held since April 2017. Previously, Dr. Selick served as Threshold Pharmaceutical’s Chief Executive Officer from June 2002 until March 2017. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation and its wholly-owned subsidiary, Camitro UK, Ltd, biotechnology companies. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Before working at Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL) he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was initially developed and commercialized by Roche for the prevention of kidney transplant rejection and more recently developed by Biogen and AbbVie and approved as Zinbryta for treatment of adults with relapsing forms of multiple sclerosis. Dr. Selick previously served as a director of Amunix Pharmaceuticals, Lead Director and Chairman of PDL, and as Chairman of the board of directors of Catalyst Biosciences and currently serves as chairman of the board of Protagonist Therapeutics, the latter two of which are currently public drug discovery and development companies. Dr. Selick received his Bachelor of Arts in Biophysics and Doctor of Philosophy in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.
Jonathan Lanfear has served on Molecular Templates’ Board of Directors since May 2018. Mr. Lanfear is currently Principal at Lanfear Advisors LLC, focusing on business development, corporate strategy and operational consulting for public and private biotechnology and biopharmaceutical companies. Previously, Mr. Lanfear was the Vice President and Global Head of R&D Business Development (BD) at Takeda Pharmaceuticals, from 2011 until September 2020, where he oversaw BD activities across Oncology, Neuroscience, Gastroenterology, and Rare Disease Therapeutic Areas. Before joining Takeda in 2011, Mr. Lanfear spent approximately 8 years at Pfizer Inc. as a Senior Director and Transactions Lead in the Worldwide Business Development, Strategy, & Innovation group. Mr. Lanfear also has previous experience in biotechnology equity research, from his time at AG Edwards/Wachovia and in business development, while at Searle/Pharmacia, where he worked on several significant licensing transactions prior to the company’s acquisition. Mr. Lanfear holds a Bachelor of Science in Chemical Engineering and a Master’s degree in Bioengineering, both from the University of Michigan (Ann Arbor), and a Master of Business Administration from Washington University (St. Louis)
David Hirsch, M.D., Ph.D.
David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently serves on the board of directors of Tricida, Inc. (TCDA), Poseida Therapeutics, Inc. (PSTX), Amunix Pharmaceuticals, Inc. and Rapid Micro Biosystems, Inc. In addition, Dr. Hirsch has previously served on the board of Collegium Pharmaceutical, Inc. (COLL) and a number of private companies. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.
David R. Hoffmann
David R. Hoffmann has served as a member of Molecular Templates’ Board of Directors since August 2017. Previously, Mr. Hoffmann served on Threshold Pharmaceutical’s Board of Directors since April 2007. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves as Chairman of the board of directors of DURECT Corporation. Mr. Hoffmann holds a Bachelor of Science in Business Administration from the University of Colorado.
Kevin M. Lalande
Kevin M. Lalande has served on Molecular Templates’ Board of Directors since March 2009. Mr. Lalande is Founding Managing Director and Chief Investment Officer of Santé, an investment partnership with $1 billion in capital under management in two different strategies. The first strategy, Santé Ventures, was founded in 2006 to create and finance innovative new healthcare and life science companies, including Molecular Templates as well as LDR Medical (Zimmer Biomet), Explorys (IBM Corp), AbVitro (Bristol Myers Squibb), Millipede Medical (Boston Scientific), TVA Medical (Becton Dickinson), Claret Medical (Boston Scientific), Lumos Pharms (Nasdaq: LUMO), and Farapulse (Boston Scientific). The second strategy, Santé Capital, is a systematic hedge fund that began trading capital in 2015 based on quantitative and natural language machine learning algorithms. Mr. Lalande conceived the investment strategy, developed the original MindRank algorithms, and assembled a seasoned team of data scientists and software engineers to help drive this business. Before his current roles, Mr. Lalande was a venture capitalist with Austin Ventures for seven years and was a management consultant with McKinsey & Company. Mr. Lalande received a bachelor’s degree with honors in Electrical & Computer Engineering, an MBA with the highest distinction from Harvard Business School, where he was both a Baker Scholar and a Siebel Scholar, and a graduate certificate in Artificial Intelligence from Stanford University.
Scott Morenstein has served as a member of Molecular Templates’ Board of Directors since August 2017. Mr. Morenstein serves as Managing Director of CAM Capital where he leads healthcare investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011.
Before joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years’ experience in biopharmaceutical investing, equity research and investment banking.
Mr. Morenstein led CAM’s investment in and served as a Director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated as a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s Board until its acquisition by Cephalon. He currently serves as a Director of Primmune Therapeutics, Palvella Therapeutics, and Antios Therapeutics and as a Board Observer for a number of public and private companies.
Mr. Morenstein received a Master of Business Administration from Harvard Business School and a Bachelor of Arts from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems.
Eric Poma, Ph.D.
Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems. (now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at Molecular Templates, he led the invention of the technology underlying Molecular Templates’ platform technology and what constitutes the whole of Molecular Templates’ current lead and preclinical pipeline candidates. Dr. Poma received his Doctor of Philosophy in Microbiology and Immunology and Bachelor of Arts in Biology from the University of North Carolina at Chapel Hill and his Master of Business Administration from New York University.
Corsee Sanders, Ph.D.
Corsee D. Sanders, Ph.D. has served as a member of Molecular Templates’ Board of Directors since December 2019. Dr. Sanders serves as a Strategic Advisor to the Global Development Group of Bristol Myers Squibb, a position she has held since November 2019. Previously, Dr. Sanders served as Strategic Advisor to the Office of the Celgene Chief Medical Officer, since March 2018, ensuring effective integration of Juno Therapeutics’ Development Organization into the Celgene Organization, specifically the unique CAR T aspects, advising the label-enabling CAR T legacy Juno program (JCAR017), and advising the Chief Medical Officer and the Chief Medical Officer’s leadership team in evolving the clinical development organization. From January 2017 to March 2018, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations. Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2011 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017, with responsibility for leading nearly 2,500 employees, across 5 strategic and 20 local country sites, in planning and conducting global development and local clinical trials in over 70 countries. She was Global Head of the Genentech/Roche Biometrics group from 2009 to 2012, and Genentech Head of DATA (Design, Analysis, Technology & Administration) prior to the Roche acquisition. Earlier in her career, she was employed at Schering-Plough Research Institute and at Centocor Inc., primarily in statistician and biomedical operations roles. Dr. Sanders has directly contributed and/or provided oversight in developing multiple approved pharmaceutical products including Claritin®, Rituxan®, Herceptin®, TNKase®, Cathflo®, Xolair, Avastin®, Tarceva®, Lucentis®, Zelboraf®, Perjeta®, Erivedge®, Gazyva®, Kadcyla®, Alecensa®, Cotellic®, Venclexta®, Tecentriq®, Ocrevus®, Hemlibra®, and JCAR017®, a CAR T cell therapy for NHL. She served as a director of TransCelerate Biopharma Inc., a non-profit organization of pharmaceutical companies until 2016 and currently serves as a member of the Board of Trustees for the Fred Hutchinson Cancer Research Center and as a director for biopharmaceutical companies, such as Beigene, Ltd., AltruBio Inc. and Legend Biotech Corporation.. Dr. Sanders earned her B.S. and M.S. in statistics, graduating Magna Cum Laude from the University of the Philippines, her M.A. and Ph.D. in statistics from the Wharton Doctoral Program at the University of Pennsylvania.